KMT2A and leukemia: Together, these findings provide strong experimental and preclinical in vivo evidence demonstrating an efficient MLL leukemia suppression by pharmacological inhibition of KDM4C, laying the foundation for future clinical application of KDM4C inhibitors in human cancer treatments.